Abstract:BACKGROUND:Medulloblastoma is the most common malignant pediatric brain tumor and group 3 subtype medulloblastoma (G3-MB) exhibits the worst prognosis. Super enhancers (SEs) are large clusters of enhancers that play important roles in cancer through transcriptional control of cell identity genes, oncogenes and tumor-dependent genes. Dissecting SE-driven transcriptional dependencies of cancer leads to identification of novel oncogenic mechanisms, therapeutic strategies and targets.METHODS:Integrative SE analyses of primary tissues and patient-derived tumor cell lines of G3-MB were performed to extract the conserved SE-associated gene signatures and their oncogenic potentials were evaluated by gene expression, tumor-dependency and patient prognosis analyses. SE-associated subtype-specific upregulated tumor-dependent genes, which were revealed as members of SE-driven core transcriptional regulatory network of G3-MB, were then subjected to functional validation and mechanistic investigation. SE-associated therapeutic potential was further explored by genetic or pharmaceutical targeting of SE complex components or SE-associated subtype-specific upregulated tumor-dependent genes individually or in combination, and the underlying therapeutic mechanisms were also examined.RESULTS:The identified conserved SE-associated transcripts of G3-MB tissues and cell lines were enriched of subtype-specifically upregulated tumor-dependent genes and MB patients harboring enrichment of those transcripts exhibited worse prognosis. Fourteen such conserved SE-associated G3-MB-specific upregulated tumor-dependent genes were identified to be members of SE-driven core transcriptional regulatory network of G3-MB, including three well-recognized TFs (MYC, OTX2 and CRX) and eleven newly identified downstream effector genes (ARL4D, AUTS2, BMF, IGF2BP3, KIF21B, KLHL29, LRP8, MARS1, PSMB5, SDK2 and SSBP3). An OTX2-SE-ARL4D regulatory axis was further revealed to represent a subtype-specific tumor dependency and therapeutic target of G3-MB via contributing to maintaining cell cycle progression and inhibiting neural differentiation of tumor cells. Moreover, BET inhibition with CDK7 inhibition or proteasome inhibition, two combinatory strategies of targeting SE complex components (BRD4, CDK7) or SE-associated effector gene (PSMB5), were shown to exhibit synergistic therapeutic effects against G3-MB via stronger suppression of SE-associated transcription or higher induction of ER stress, respectively.CONCLUSIONS:Our study verifies the oncogenic role and therapeutic potential of SE-driven transcriptional dependencies of G3-MB, resulting in better understanding of its tumor biology and identification of novel SE-associated therapeutic strategies and targets.

Development and validation of a 23-gene expression signature for molecular subtyping of medulloblastoma in a long-term Chinese cohort

Identification and Validation of a 23-Gene Expression Signature for Subtype Classification of Medulloblastoma.

Identification of molecular subtypes and a prognostic signature based on chromatin regulators related genes in prostate cancer

Dissecting Super-Enhancer Driven Transcriptional Dependencies Reveals Novel Therapeutic Strategies and Targets for Group 3 Subtype Medulloblastoma.

An Immune Microenvironment-Associated Gene Signature Predicts Outcomes and Therapeutic Response in Pediatric Medulloblastoma

Multi-omics analysis of intertumoral heterogeneity within medulloblastoma uncharted-pathway subtypes

Single‐Cell Chromatin Accessibility Analysis Reveals Subgroup‐Specific TF‐NTR Regulatory Circuits in Medulloblastoma

Molecular Subgroups of Adult Medulloblastoma: a Long-Term Single-Institution Study.

Development and Validation of Radiomic Signatures of Head and Neck Squamous Cell Carcinoma Molecular Features and Subtypes.

PDTB-08. Mir-449a, A POTENTIAL DIAGNOSTIC BIOMARKER FOR WNT GROUP OF MEDULLOBLASTOMA

Advancing presurgical non-invasive molecular subgroup prediction in medulloblastoma using artificial intelligence and MRI signatures

Accuracy analysis of identifying molecular subtypes of children and adolescents with medulloblastoma using real-time fluorescence quantitative PCR

Metabolomic profiling of childhood medulloblastoma: contributions and relevance to diagnosis and molecular subtyping

Transcriptomic Profiling Identifies a Nucleotide Metabolism-Related Signature with Prognostic Power in Gliomas

MR Imaging–Based Radiomic Signatures of Distinct Molecular Subgroups of Medulloblastoma

Radiomic Features From Multi-Parameter MRI Combined With Clinical Parameters Predict Molecular Subgroups in Patients With Medulloblastoma

Machine Learning-Driven Identification of Molecular Subgroups in Medulloblastoma via Gene Expression Profiling

Medulloblastoma: Molecular understanding, treatment evolution, and new developments

A Retrospective Study of Progression-Free and Overall Survival in Pediatric Medulloblastoma Based on Molecular Subgroup Classification: A Single-Institution Experience.

A Unified 35-Gene Signature For Both Subtype Classification And Survival Prediction In Diffuse Large B-Cell Lymphomas

Systematic transcriptomic analysis of childhood medulloblastoma identifies N6- methyladenosine-dependent lncRNA signatures associated with molecular subtype, immune cell in fi ltration, and prognosis